Back to results
US 2021/0228700 A1Published application
High-affinity anti-vegf antibody
AssigneesOrder-Made Medical Research Inc., Santen Pharmaceutical Co., Ltd.
InventorsYasufumi MURAKAMI, Shigeki MUKOUBATA, Hirotada AKIYAMA, Koji KONOMI
Life of this patent
Estimating the term…
Abstract
An object of the present invention is to provide an antibody having significantly high affinity for VEGF compared to the prior art. The present invention provides a monoclonal antibody against VEGF, which binds to a vascular endothelial growth factor (VEGF) with a dissociation constant of 1×10−11 mol/L or less.
Claims21
A monoclonal antibody against VEGF, or an antigen-binding fragment thereof, that binds to a vascular endothelial growth factor (VEGF), comprising:
- CDR-H1 that comprises the amino acid sequence of SEQ ID NO:
- 14, CDR-H2 that comprises the amino acid sequence of SEQ ID NO:
- 16, and CDR-H3 that comprises the amino acid sequence of SEQ ID NO:
- 18;
- and CDR-L1 that comprises the amino acid sequence of SEQ ID NO:
- 20, CDR-L2 that comprises the amino acid sequence of Trp-Ala-Ser, and CDR-L3 that comprises the amino acid sequence of SEQ ID NO:
- 22.
4 more elements
Dependencies are inferred from the claim text.